MarginsXMarginsX
Home › Markets › Health Care › NTLA

Intellia Therapeutics Inc. (NTLA)

NTLA trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.86
+1.65% on the day
Market cap
$1.4B
Small cap
Revenue · 2025
$67.7M
+16.9% on 2024
Net income · 2025
-$412.7M
-609.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/0001193125-26-076550-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNTLA on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO year2016
SEC CIK0001652130
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2025

LineValue
Revenue$67.7M
Net income-$412.7M
Operating income-$441.0M
Net margin-609.9%
Operating margin-651.7%
Revenue growth+16.9%
Cash$155.5M
Total assets$842.1M
P/E (computed)Net income was not positive
P/S (computed)20.5×

Warning signs

Cash runway
5.3 months
$156.1M cash at September 30, 2026
Share count, 1 year
+21.2%
2025-10-31 to 2026-10-30 · +56.7% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$771K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$156.1M cash; operating cash flow -$88.8M a quarter.Report 2026-09-30
Shares outstanding140,358,512 (2026-10-30); 115,829,926 a year earlier; 89,554,891 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-04-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.4M, sold $2.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$7.2M-$127.5M-$85.4M$156.1M$73.7M$52.9M10-Q 2026-11-05
Q2 2026
2026-06-30
$7.7M-$106.6M-$83.1M$106.1MNo debt tags$59.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$15.0M-$96.2M-$117.3M$134.7MNo debt tags$66.1M10-Q 2026-05-11
Q4 2025
2025-12-31
$23.0M-$95.8M-$69.3M$155.5M$0$67.7M10-K 2026-02-26
Q3 2025
2025-09-30
$13.8M-$101.3M-$76.9M$193.4MNo debt tags$57.5M10-Q 2026-11-05
Q2 2025
2025-06-30
$14.2M-$101.3M-$99.6M$156.2MNo debt tags$52.9M10-Q 2026-08-06
Q1 2025
2025-03-31
$16.6M-$114.3M-$148.9M$126.9MNo debt tags$45.6M10-Q 2026-05-11
Q4 2024
2024-12-31
$12.9M-$128.9M-$85.2M$189.2MNo debt tags$57.9M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-29
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K/A2026-11-13
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 726 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-14.5%
1 month-18.6%
3 months-18.0%
Year to date+7.9%
1 year+11.9%
From 52-week high-45.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
NEOGNeogen Corporation$10.88-3.12%$2.4B
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
NNNNAnbio Biotechnology$3.88+1.57%$558.3M
MYGNMyriad Genetics Inc.$5.57-1.59%$534.3M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M
LNTHLantheus Holdings Inc.$101.72+0.13%$6.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier